|
1.
|
Masaoka A, Monden Y, Nakahara K and
Tanioka T: Follow-up study of thymomas with special reference to
their clinical stages. Cancer. 48:2485–2492. 1981.
|
|
2.
|
Blumberg D, Port JL, Weksler B, et al:
Thymoma: a multivariate analysis of factors predicting survival.
Ann Thorac Surg. 60:908–913. 1995.
|
|
3.
|
Kondo K and Monden Y: Therapy for thymic
epithelial tumors: a clinical study of 1,320 patients from Japan.
Ann Thorac Surg. 76:878–884. 2003.
|
|
4.
|
Tateyama H, Mizuno T, Tada T, Eimoto T,
Hashimoto T and Masaoka A: Thymic epithelial tumours: evaluation of
malignant grade by quantification of proliferating cell nuclear
antigen and nucleolar organizer regions. Virchows Arch A Pathol
Anat Histopathol. 422:265–269. 1993.
|
|
5.
|
Tateyama H, Eimoto T, Tada T, Mizuno T,
Inagaki H, Hata A, Sasaki M and Masaoka A: p53 protein expression
and p53 gene mutation in thymic epithelial tumors. An
immunohistochemical and DNA sequencing study. Am J Clin Pathol.
104:375–381. 1995.
|
|
6.
|
Pich A, Chiarle R, Chiusa L, Ponti R,
Geuna M, Casadio C, Maggi G and Palestro G: Long-term survival of
thymoma patients by histologic pattern and proliferative activity.
Am J Surg Pathol. 19:918–926. 1995.
|
|
7.
|
Yang WI, Efird JT, Quintanilla-Martinez L,
Choi N and Harris NL: Cell kinetic study of thymic epithelial
tumors using PCNA (PC10) and Ki-67 (MIB-1) antibodies. Hum Pathol.
27:70–76. 1996.
|
|
8.
|
Chen FF, Yan JJ, Jin YT and Su IJ:
Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a
reliable marker of tumor aggressiveness. Hum Pathol. 27:1089–1092.
1996.
|
|
9.
|
Tateyama H, Eimoto T, Tada T, Inagaki H,
Hattori H and Takino H: Apoptosis, bcl-2 protein, and Fas antigen
in thymic epithelial tumors. Mod Pathol. 10:983–991. 1997.
|
|
10.
|
Takahashi E, Tateyama H, Akatsu H, Fukai
I, Yamakawa Y, Fujii Y and Eimoto T: Expression of matrix
metalloproteinases 2 and 7 in tumor cells correlates with the World
Health Organization classification subtype and clinical stage of
thymic epithelial tumors. Hum Pathol. 34:1253–1258. 2003.
|
|
11.
|
Tateyama H, Sugiura H, Yamatani C and Yano
M: Expression of podoplanin in thymoma: its correlation with tumor
invasion, nodal metastasis, and poor clinical outcome. Hum Pathol.
42:533–540. 2011.
|
|
12.
|
Koga K, Matsuno Y, Noguchi M, Mukai K,
Asamura H, Goya T and Shimosato Y: A review of 79 thymomas:
modification of staging system and reappraisal of conventional
division into invasive and non-invasive thymoma. Pathol Int.
44:359–367. 1994.
|
|
13.
|
Huang J, Detterbeck FC, Wang Z and Loehrer
PJ Sr: Standard outcome measures for thymic malignancies. J Thorac
Oncol. 5:2017–2023. 2010.
|
|
14.
|
Travis WD, Brambilla E, Muller-Hermelink
HK and Harris CC: World Health Organization classification of
Tumours. Pathology and Genetics of Tumours of the Lung, Pleura,
Thymus and Heart. IARC Press; Lyon: pp. 146–151. 2004
|
|
15.
|
Onuki T, Ishikawa S, Iguchi K, et al:
Limited thymectomy for stage I or II thymomas. Lung Cancer.
68:460–465. 2010.
|
|
16.
|
Okumura M, Ohta M, Tateyama H, Nakagawa K,
Matsumura A, Maeda H, Tada H, Eimoto T, Matsuda H and Masaoka A:
The World Health Organization histologic classification system
reflects the oncologic behavior of thymoma: a clinical study of 273
patients. Cancer. 94:624–632. 2002.
|
|
17.
|
Pollack A, DeSilvio M, Khor LY, et al:
Ki-67 staining is a strong predictor of distant metastasis and
mortality for men with prostate cancer treated with radiotherapy
plus androgen deprivation: Radiation Therapy Oncology Group Trial
92-02. J Clin Oncol. 22:2133–2140. 2004.
|
|
18.
|
Yerushalmi R, Woods R, Ravdin PM, Hayes MM
and Gelmon KA: Ki67 in breast cancer: prognostic and predictive
potential. Lancet Oncol. 11:174–183. 2010.
|
|
19.
|
Ghazi AA, Dezfooli AA, Mohamadi F, Yousefi
SV, Amirbaigloo A, Ghazi S, Pourafkari M, Berney D, Ellard S and
Grossman AB: Cushing syndrome secondary to a thymic carcinoid tumor
due to multiple endocrine neoplasia type 1. Endocr Pract.
17:e92–e96. 2011.
|
